Assignee
MORPHOSYS AG
DE·58 granted patents·58 pending applications·1,770 citations·filing 1995–2025
Top patents by PatentIndex Score
116 records- 0197US6300064B1Protein/(poly)peptide librariesMORPHOSYS AG·Filed 1998·Granted Oct 9, 2001·794 cites·25 claims
- 0295US6706484B1Protein/(poly)peptide librariesMORPHOSYS AG·Filed 2000·Granted Mar 16, 2004·158 cites·35 claims
- 0394US9758590B2Anti-CD38 human antibodies and uses thereofMORPHOSYS AG·Filed 2015·Granted Sep 12, 2017·15 cites·3 claims
- 0494US6753136B2Methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bondsMORPHOSYS AG·Filed 2001·Granted Jun 22, 2004·72 cites·19 claims
- 0594US6696248B1Protein/(poly)peptide librariesMORPHOSYS AG·Filed 2000·Granted Feb 24, 2004·112 cites·74 claims
- 0693US7264963B1Protein(poly)peptide librariesMORPHOSYS AG·Filed 2000·Granted Sep 4, 2007·104 cites·13 claims
- 0793US6294353B1Targeted hetero-association of recombinant proteins to multi-functional complexesMORPHOSYS AG·Filed 1995·Granted Sep 25, 2001·175 cites·29 claims
- 0892US7867495B2Anti-GM-CSF antibodies and uses thereforMORPHOSYS AG·Filed 2006·Granted Jan 11, 2011·25 cites·54 claims
- 0991US6653068B2Generation of specific binding partners binding to (poly)peptides encoded by genomic DNA fragments or ESTsMORPHOSYS AG·Filed 2001·Granted Nov 25, 2003·95 cites·32 claims
- 1090US9193799B2Fully human therapeutic antibodies specific for human CD38MORPHOSYS AG·Filed 2013·Granted Nov 24, 2015·10 cites·40 claims
- 1188US2024309109A1Generation and profiling of fully human therapeutic antibodies specific for human cd38MORPHOSYS AG·Filed 2024·Application pending·0 cites
- 1287US11702463B2Canine antibody librariesMORPHOSYS AG·Filed 2021·Granted Jul 18, 2023·1 cites·20 claims
- 1387US9289490B2Combinations and uses thereofMORPHOSYS AG·Filed 2014·Granted Mar 22, 2016·10 cites·20 claims
- 1487US6828422B1Protein/(poly)peptide librariesMORPHOSYS AG·Filed 2000·Granted Dec 7, 2004·95 cites·59 claims
- 1586US11059902B2Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38MORPHOSYS AG·Filed 2018·Granted Jul 13, 2021·1 cites·7 claims
- 1686US10259869B2Antibodies for IL-17CMORPHOSYS AG·Filed 2018·Granted Apr 16, 2019·6 cites·11 claims
- 1786US10184005B2Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38MORPHOSYS AG·Filed 2015·Granted Jan 22, 2019·4 cites·24 claims
- 1885US11224654B2Combinations and uses thereofMORPHOSYS AG·Filed 2016·Granted Jan 18, 2022·2 cites·18 claims
- 1985US11014978B2Canine antibody librariesMORPHOSYS AG·Filed 2018·Granted May 25, 2021·2 cites·17 claims
- 2083US10633439B2Antibodies for IL-17CMORPHOSYS AG·Filed 2019·Granted Apr 28, 2020·2 cites·18 claims
- 2183US9486547B2Radiolabelled antibody and uses thereofMORPHOSYS AG·Filed 2013·Granted Nov 8, 2016·6 cites·16 claims
- 2283US7049135B2Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complexMORPHOSYS AG·Filed 2003·Granted May 23, 2006·15 cites·26 claims
- 2383US2025074978A1Antibodies for il-17cMORPHOSYS AG·Filed 2024·Application pending·0 cites
- 2482US11254734B2Fab molecules with a rodent hinge region and a non-rodent CH1 regionMORPHOSYS AG·Filed 2017·Granted Feb 22, 2022·2 cites·7 claims
- 2582US6692935B1Targeted hetero-association of recombinant proteins to multi-functional complexesMORPHOSYS AG·Filed 2000·Granted Feb 17, 2004·16 cites·26 claims
- 2681US10617691B2Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2016·Granted Apr 14, 2020·3 cites·16 claims
- 2781US2024392034A1Clinical assessment of m-protein response in multiple myelomaMORPHOSYS AG·Filed 2024·Application pending·0 cites
- 2880US11987621B2Antibodies for IL-17CMORPHOSYS AG·Filed 2020·Granted May 21, 2024·1 cites·17 claims
- 2980US6667150B1Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly) peptide complexMORPHOSYS AG·Filed 2000·Granted Dec 23, 2003·23 cites·36 claims
- 3079US11939395B2Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38MORPHOSYS AG·Filed 2021·Granted Mar 26, 2024·0 cites·6 claims
- 3179US9541559B2Collection and methods for its useMORPHOSYS AG·Filed 2014·Granted Jan 10, 2017·2 cites·32 claims
- 3278US9765152B2Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomibMORPHOSYS AG·Filed 2016·Granted Sep 19, 2017·2 cites·14 claims
- 3377US12018072B2Antibodies specific for human complement C5A receptor (C5AR)MORPHOSYS AG·Filed 2023·Granted Jun 25, 2024·0 cites·30 claims
- 3477US9579378B2Combinations and uses thereofMORPHOSYS AG·Filed 2013·Granted Feb 28, 2017·4 cites·16 claims
- 3577US8367586B2Collection and methods for its useMORPHOSYS AG·Filed 2011·Granted Feb 5, 2013·2 cites·30 claims
- 3677US2024417455A1Treatment for rheumatoid arthritisMORPHOSYS AG·Filed 2024·Application pending·0 cites
- 3776US10913792B2Treatment for rheumatoid arthritisMORPHOSYS AG·Filed 2018·Granted Feb 9, 2021·1 cites·7 claims
- 3876US10774154B2Complex-specific antibodies and antibody fragments and its useMORPHOSYS AG·Filed 2017·Granted Sep 15, 2020·1 cites·6 claims
- 3976US10655125B2Polypeptide libraryMORPHOSYS AG·Filed 2017·Granted May 19, 2020·1 cites·16 claims
- 4076US2023203189A1Clinical assessment of m-protein response in multiple myelomaMORPHOSYS AG·Filed 2023·Application pending·0 cites
- 4175US9624293B2Collection and methods for its useMORPHOSYS AG·Filed 2014·Granted Apr 18, 2017·1 cites·14 claims
- 4275US7785859B2Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bondsMORPHOSYS AG·Filed 2003·Granted Aug 31, 2010·4 cites·32 claims
- 4374US10308722B2Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomideMORPHOSYS AG·Filed 2017·Granted Jun 4, 2019·1 cites·20 claims
- 4474US2024009196A1Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2023·Application pending·0 cites
- 4574US2024400657A1Antibodies targeting c5arMORPHOSYS AG·Filed 2024·Application pending·0 cites
- 4672US11542329B2Antibodies targeting Glycoprotein VIMORPHOSYS AG·Filed 2019·Granted Jan 3, 2023·1 cites·18 claims
- 4771US2021347879A1Anti-gm-csf antibodiesMORPHOSYS AG·Filed 2021·Application pending·0 cites
- 4871US2022283166A1Methods for predicting therapeutic benefit of anti-cd19 therapy in patientsMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 4970US11028165B2Nucleic acid encoding anti-GM-CSF antibodiesMORPHOSYS AG·Filed 2019·Granted Jun 8, 2021·0 cites·14 claims
- 5070US10533057B2Treatment for multiple myeloma (MM)MORPHOSYS AG·Filed 2016·Granted Jan 14, 2020·1 cites·5 claims
Showing the top 50 of 116 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MORPHOSYS AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →